Nektar Therapeutics (LON:0UNL)
56.82
-0.57 (-0.99%)
Dec 10, 2025, 4:56 PM BST
Nektar Therapeutics Revenue
Nektar Therapeutics had revenue of $11.79M USD in the quarter ending September 30, 2025, a decrease of -51.13%. This brings the company's revenue in the last twelve months to $62.60M, down -32.79% year-over-year. In the year 2024, Nektar Therapeutics had annual revenue of $98.43M with 9.22% growth.
Revenue (ttm)
$62.60M
Revenue Growth
-32.79%
P/S Ratio
19.28
Revenue / Employee
$1.03M
Employees
61
Market Cap
898.06M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 98.43M | 8.31M | 9.22% |
| Dec 31, 2023 | 90.12M | -1.93M | -2.10% |
| Dec 31, 2022 | 92.06M | -9.85M | -9.67% |
| Dec 31, 2021 | 101.91M | -51.01M | -33.36% |
| Dec 31, 2020 | 152.92M | 38.30M | 33.41% |
| Dec 31, 2019 | 114.62M | -1.08B | -90.40% |
| Dec 31, 2018 | 1.19B | 885.61M | 287.81% |
| Dec 31, 2017 | 307.71M | 142.28M | 86.00% |
| Dec 31, 2016 | 165.44M | -65.35M | -28.32% |
| Dec 31, 2015 | 230.78M | 30.08M | 14.99% |
| Dec 31, 2014 | 200.71M | 51.79M | 34.77% |
| Dec 31, 2013 | 148.92M | 67.73M | 83.42% |
| Dec 31, 2012 | 81.19M | 9.71M | 13.59% |
| Dec 31, 2011 | 71.48M | -87.56M | -55.06% |
| Dec 31, 2010 | 159.04M | 87.11M | 121.10% |
| Dec 31, 2009 | 71.93M | -18.25M | -20.24% |
| Dec 31, 2008 | 90.19M | -182.84M | -66.97% |
| Dec 31, 2007 | 273.03M | 55.31M | 25.40% |
| Dec 31, 2006 | 217.72M | 91.44M | 72.41% |
| Dec 31, 2005 | 126.28M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| Genus | 672.80M |
| HUTCHMED (China) | 439.54M |
Nektar Therapeutics News
- 5 weeks ago - Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London - PRNewsWire
- 6 weeks ago - Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets - PRNewsWire
- 6 weeks ago - San Francisco is making a comeback. So are these stocks from the City by the Bay - CNBC
- 7 weeks ago - Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting - PRNewsWire
- 7 weeks ago - Nektar Therapeutics (NKTR) Rises on Takeover Speculation - GuruFocus
- 7 weeks ago - Nektar (NKTR) Shares Surge on M&A Rumor - GuruFocus
- 7 weeks ago - Nektar Therapeutics gains amid takeover speculation - Seeking Alpha
- 2 months ago - Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September - The Motley Fool